Advertisement

Melatonin Action on Human Breast Cancer Cells: Involvement of Glutathione Metabolism and the Redox Environment

  • David E. Blask
  • Sean T. Wilson
Chapter
Part of the NATO ASI Series book series (NSSA, volume 277)

Abstract

In spite of the evidence that melatonin inhibits breast cancer growth in vivo and in vitro (1,2), very little is known regarding the mechanism(s) of action by which this indoleamine exerts its oncostatic action (3). Recently, some progress has been made in elucidating melatonin’s mechanism of action at the cellular level using the estrogen receptor (ER) + human breast cancer cell line MCF-7. In this cell line, physiological concentrations of melatonin retard cell growth by delaying the progression of cells from G0/ G1 to S phase of the cell cycle (4). Furthermore, melatonin not only blocks estrogen-stimulated MCF-7 cell growth, but it also down-regulates the expression of ER protein as well as ER mRNA (5,6) while transiently increasing the expression of c-fos (7). Additionally, melatonin inhibits the mitogenic action of other peptide growth factors such as prolactin and epidermal growth factor (8,9). Also, the antiproliferative action of physiological levels of melatonin appears to be restricted to ER+ human breast cancer since ER- cells have little or no response to this indole (10).

Keywords

Human Breast Cancer Cell Human Breast Cancer Cell Line Ethacrynic Acid Buthionine Sulfoximine Estrogen Receptor mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D.E. Blask, D.B. Pelletier, S.M. Hill, A. Lemus-Wilson, D.S. Grosso, S.T. Wilson and M.E. Wise, Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo, J. Cancer Res. Clin. Oncol. 117:526 (1991).CrossRefGoogle Scholar
  2. 2.
    S.M. Hill, and D.E. Blask, Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture, Cancer Res., 48:6121 (1988).PubMedGoogle Scholar
  3. 3.
    D.E. Blask, Melatonin in oncology, in: “Melatonin Biosynthesis, Physiological Effects,and Clinical Applications,” H.S. Yu, and R.J. Reiter, eds., CRC Press, Boca Raton, 447 (1993).Google Scholar
  4. 4.
    S. Cos, D.E. Blask, A. Lemus-Wilson, and A.B. Hill, Effects of melatonin on the cell cycle kinetics and “estrogen-rescue” of MCF-7 human breast cancer cells in culture, J. Pineal Res., 10:36 (1991).PubMedCrossRefGoogle Scholar
  5. 5.
    T.M. Molis, M.R. Walters, and S.M. Hill, Melatonin modulation of estrogen receptor expresssion in MCF-7 human breast cancer cells, Int. J. Oncol. 3:687 (1993).PubMedGoogle Scholar
  6. 6.
    T.M. Molis, Y. Cockerham, and S.M. Hill, Regulation of ER mRNA expression by melatonin in MCF-7 human breast cancer cells, 74th Ann. Mtg. Endocr. Soc., Abs. 1030, 309 (1992).Google Scholar
  7. 7.
    K.M. Hull, T.J. Maher, and K.L. Jorgenson, Melatoin increases c-fos mRNA in MCF-7 human breast cancer cells, Soc. Neurosci., 19:Abs. 773.5, 1896 (1993).Google Scholar
  8. 8.
    A. Lemus-Wilson, D.E. Blask , and P.A. Kelly, Direct inhibitory effect of melatonin on prolactin receptor-mediated growth of MCF-7 human breast cancer cells, 74th Ann. Mtg. Endocr. Soc., Abs. 1297, 376 (1992).Google Scholar
  9. 9.
    S. Cos, and D.E. Blask, Melatonin modulates growth factor activity in MCF-7 human breast cancer cells, J. Pineal Res., (1994) in press.Google Scholar
  10. 10.
    S.M. Hill, L.L. Spriggs, M.A. Simon, H. Muraoka, and D.E. Blask, The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system, Cancer Lett., 64:249 (1992).PubMedCrossRefGoogle Scholar
  11. 11.
    R.J. Reiter, Melatonin: multifaceted messenger to the masses, Lab. Med., 25:438 (1994).Google Scholar
  12. 12.
    R.J. Reiter, D.X Tan, B. Poeggler, A. Menendez-Pelaez, L.D. Chen, and S. Saarela,Melatonin as a free radical scavenger: implications for aging and age-related diseases, Ann. N.Y. Acad. Sci., 719:1 (1994).PubMedCrossRefGoogle Scholar
  13. 13.
    L. Kothari, and A. Subramanian, A possible modulatory influence of melatonin on representative phase I and phase II drug metabolizing enzymes in 9, 10-dimethyl-1,2-benzanthracene induced rat mammary tumorigenesis, Anti-Cancer Drugs, 3: 623 (1992).PubMedCrossRefGoogle Scholar
  14. 14.
    D.E. Blask, S.T. Wilson, and A.M. Lemus-Wilson, The oncostatic and oncomodulatory role of the pineal gland and melatonin, in: “Advances in Pineal Research”, vol. 7, G.J.M. Maestroni, A. Conti, and R.J. Reiter, eds., John Libbey, London, 235, (1994).Google Scholar
  15. 15.
    A. Meister, Glutathione, ascorbate, and cellular protection, Cancer Res., 54:1969s (1994).Google Scholar
  16. 16.
    J.P. Shaw, and I.N. Chou, Elevation of intracellular glutathione content associated with mitogenic stimulation of quiescent fibroblasts, J. Cell. Physiol., 129:193 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    J.E. Leibmann, S.M. Hahn, J.A. Cook, C. Lipschultz, J.B. Mitchell, and D.C. Kaufman,Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity, Cancer Res., 53:2066 (1993).Google Scholar
  18. 18.
    S. Simon, and M. Schindler, Cell biological mechanisms of multidrug resistance in tumors, Proc. Natl. Acad. Sci. USA, 91:3497 (1994).PubMedCrossRefGoogle Scholar
  19. 19.
    B.A. Arrick, and C.F. Nathan, Glutathione metabolism as a determinant of therapeutic efficacy: a review, Cancer Res., 44:4224 (1984).PubMedGoogle Scholar
  20. 20.
    A. Meister, and M.E. Anderson, Glutathione, Ann. Rev. Biochem., 52:711 (1983).PubMedCrossRefGoogle Scholar
  21. 21.
    D.J. Waxman, Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy -a review, Cancer Res., 50:6449 (1990).PubMedGoogle Scholar
  22. 22.
    R.D.H. Whelan, L.K. Hosking, A.J. Townsend, K.H. Cowan, and B.T. Hill, Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines, Cancer Commun., 1:359 (1990).Google Scholar
  23. 23.
    G. Batist, R. Schecter, A. Woo, D. Greene, and S. Lehnert, Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines, Biochem. Pharmacol, 41:631 (1991).PubMedCrossRefGoogle Scholar
  24. 24.
    D.K. Armstrong, G.B. Gordon, J. Hilton, R.T. Streeper, O.M. Colvin, N.E. Davidson,Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance, Cancer Res., 52:1416 (1992).PubMedGoogle Scholar
  25. 25.
    R.A. Kramer, J. Zakher, and G Kim, Role of the glutathione redox cycle in acquired and de novo multidrug resistance, Science, 241:694 (1988).PubMedCrossRefGoogle Scholar
  26. 26.
    A. Meister, Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy, Pharmac. Ther., 51:155 (1991).CrossRefGoogle Scholar
  27. 27.
    K.D. Tew, A.M. Bomber, and S.J. Hoffman, Ethacrynic acid and piripost as enhancers of cytotoxicity in drug resistant and sensitive cell lines, Cancer Res., 48:3622 (1988).PubMedGoogle Scholar
  28. 28.
    J.H.T.M. Ploemen, A. Van Schanke, B. Van Ommen, and P.J. Van Bladeren, Reversible conjugation of ethacrynic acid with glutathione and human glutathione S-transferase P1–1, Cancer Res., 54:915 (1994).PubMedGoogle Scholar
  29. 29.
    Y. Takamatsu, and T. Inaba, Inhibition of human hepatic glutathione S-transferase isozymes by ethacrynic acid and its metabolites, Toxicol. Lett., 62:241 (1992).PubMedCrossRefGoogle Scholar
  30. 30.
    A.F. Howie, W.R. Miller, R.A. Hawkins, A.R. Hutchinson, and G.J. Beckett,Expression of glutathione S-transferase B1 , B2 , Mu and Pi in breast cancers an their relationship to oestrogen receptor status, Br. J. Cancer, 60:834 (1989).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • David E. Blask
    • 1
  • Sean T. Wilson
    • 1
  1. 1.The Mary Imogene Bassett Research InstituteCooperstownUSA

Personalised recommendations